Please login to the form below

Not currently logged in
Email:
Password:

Merck KGaA’s Oschmann elected president of IFPMA

He takes over from Lilly’s John Lechleiter
Stefan Oschmann, IFPMA

Global pharma trade body the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has elected Merck KGaA's Stefan Oschmann as its new president.

Oschmann is currently CEO of Merck's pharma business but is due to become deputy CEO of the entire group at the beginning of next year in a shake-up of Merck's leadership.

He succeeds John Lechleiter, chairman, president and CEO at Lilly, who has completed his two-year term after taking over from former AstraZeneca CEO David Brennan.

Oschmann has worked in life sciences for several decades, including roles early in his career at the German Animal Health Federation and the German Chemical Industry Association.

His pharma experience includes an 11-year spell at Merck's US-based namesake Merck & Co, known as MSD outside the US and Canada, before joining Germany-based Merck in 2011.

As president of IFPMA he will head the organisation's work as it engages with international organisations and global health stakeholders on global health policy issues with a focus on innovation and access to quality pharmaceuticals.

Oschmann said he was honoured to take over the role at an important time for global health.

“Current challenges around non-communicable diseases and infectious diseases demonstrate the need for stronger health systems as well as for local innovative solutions in low and middle income countries,” he said.

“As an industry, we will continue to explore how the research-based pharmaceutical industry can sustainably meet the needs and expectations of patients and societies, building on our transformational partnerships to support health goals in these countries.”

5th November 2014

From: Research, Sales, Marketing, Regulatory, Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....